Elevara Medicines appoints biotech veteran as CEO

14 July 2026

UK clinical-stage biotech Elevara Medicines today announced the appointment of Mai-Britt Zocca as chief executive (CEO), effective 1 July 2026. Dr Zocca succeeds founder and CEO Emma Tinsley and will lead the company into its next phase of growth. Ms Tinsley will remain on the board as a non-executive director.

“Mai-Britt is an exceptional biotechnology leader,” said Emma Tinsley, outgoing CEO of Elevara. “She combines deep scientific understanding with extensive operational and public company experience, and has successfully built organizations through exactly the stage Elevara is now entering. As we got to know Mai-Britt through the selection process, it became increasingly clear that she was the right person to lead the company into its next chapter. I am delighted to welcome her to Elevara.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK